BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1184 related articles for article (PubMed ID: 25449570)

  • 21. PrP P102L and Nearby Lysine Mutations Promote Spontaneous
    Kraus A; Raymond GJ; Race B; Campbell KJ; Hughson AG; Anson KJ; Raymond LD; Caughey B
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PrP aggregation can be seeded by pre-formed recombinant PrP amyloid fibrils without the replication of infectious prions.
    Barron RM; King D; Jeffrey M; McGovern G; Agarwal S; Gill AC; Piccardo P
    Acta Neuropathol; 2016 Oct; 132(4):611-24. PubMed ID: 27376534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of prion adaptation and evolution paradigm for human neurodegenerative diseases.
    Kabir ME; Safar JG
    Prion; 2014; 8(1):111-6. PubMed ID: 24401672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new mechanism for transmissible prion diseases.
    Makarava N; Kovacs GG; Savtchenko R; Alexeeva I; Ostapchenko VG; Budka H; Rohwer RG; Baskakov IV
    J Neurosci; 2012 May; 32(21):7345-55. PubMed ID: 22623680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PrP N-terminal domain triggers PrP(Sc)-like aggregation of Dpl.
    Erlich P; Cesbron JY; Lemaire-Vieille C; Curt A; Andrieu JP; Schoehn G; Jamin M; Gagnon J
    Biochem Biophys Res Commun; 2008 Jan; 365(3):478-83. PubMed ID: 17997980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of genuine prion infectivity by serial PMCA.
    Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
    Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prion-like disorders and Transmissible Spongiform Encephalopathies: An overview of the mechanistic features that are shared by the various disease-related misfolded proteins.
    Eraña H; Venegas V; Moreno J; Castilla J
    Biochem Biophys Res Commun; 2017 Feb; 483(4):1125-1136. PubMed ID: 27590581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From molecule to molecule and cell to cell: prion-like mechanisms in amyotrophic lateral sclerosis.
    Grad LI; Fernando SM; Cashman NR
    Neurobiol Dis; 2015 May; 77():257-65. PubMed ID: 25701498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates.
    Soto C; Estrada L; Castilla J
    Trends Biochem Sci; 2006 Mar; 31(3):150-5. PubMed ID: 16473510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prions and Protein Assemblies that Convey Biological Information in Health and Disease.
    Sanders DW; Kaufman SK; Holmes BB; Diamond MI
    Neuron; 2016 Feb; 89(3):433-48. PubMed ID: 26844828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid formation of amyloid from alpha-monomeric recombinant human PrP in vitro.
    Tahiri-Alaoui A; James W
    Protein Sci; 2005 Apr; 14(4):942-7. PubMed ID: 15741327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human prion protein fragment 90-231, a useful model to study prion neurotoxicity.
    Corsaro A; Thellung S; Villa V; Nizzari M; Aceto A; Florio T
    OMICS; 2012; 16(1-2):50-9. PubMed ID: 22321015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The spread of prion-like proteins by lysosomes and tunneling nanotubes: Implications for neurodegenerative diseases.
    Victoria GS; Zurzolo C
    J Cell Biol; 2017 Sep; 216(9):2633-2644. PubMed ID: 28724527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic prions with novel strain-specified properties.
    Moda F; Le TN; Aulić S; Bistaffa E; Campagnani I; Virgilio T; Indaco A; Palamara L; Andréoletti O; Tagliavini F; Legname G
    PLoS Pathog; 2015 Dec; 11(12):e1005354. PubMed ID: 26720726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction between misfolded PrP and the ubiquitin-proteasome system in prion-mediated neurodegeneration.
    Lin Z; Zhao D; Yang L
    Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):477-84. PubMed ID: 23449072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prion protein misfolding, strains, and neurotoxicity: an update from studies on Mammalian prions.
    Poggiolini I; Saverioni D; Parchi P
    Int J Cell Biol; 2013; 2013():910314. PubMed ID: 24454379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prion protein: structural features and related toxicity.
    Hu PP; Huang CZ
    Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):435-41. PubMed ID: 23615535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different tau fibril types reduce prion level in chronically and de novo infected cells.
    Celauro L; Burato A; Zattoni M; De Cecco E; Fantuz M; Cazzaniga FA; Bistaffa E; Moda F; Legname G
    J Biol Chem; 2023 Aug; 299(8):105054. PubMed ID: 37454740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The propagation of prion-like protein inclusions in neurodegenerative diseases.
    Goedert M; Clavaguera F; Tolnay M
    Trends Neurosci; 2010 Jul; 33(7):317-25. PubMed ID: 20493564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion.
    Silva JL; Vieira TC; Gomes MP; Rangel LP; Scapin SM; Cordeiro Y
    Methods; 2011 Mar; 53(3):306-17. PubMed ID: 21145399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.